Kyowa Kirin licenses in transdermal granisetron for four Asian markets
This article was originally published in Scrip
Executive Summary
Kyowa Hakko Kirin is strengthening its oncology business in Asia through the acquisition of exclusive marketing rights to a transdermal patch formulation of granisetron in selected markets.